SpringWorks Therapeutics, Inc. Common Stock
SWTX
SWTX: SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
moreShow SWTX Financials
Recent trades of SWTX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Christopher L. Jacobs House / R | Purchase $1,001 - $15,000 | Dec. 12, 2022 |
Recently reported changes by institutional investors
Quarterly net insider trading by SWTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Feb. 07, 2023
-
Patent Title: Solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof Aug. 30, 2022
-
Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Aug. 10, 2021
Federal grants, loans, and purchases
Followers on SWTX's company Twitter account
Number of mentions of SWTX in WallStreetBets Daily Discussion
Recent insights relating to SWTX
Recent picks made for SWTX stock on CNBC
ETFs with the largest estimated holdings in SWTX
Flights by private jets registered to SWTX